Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Biochem J ; 467(1): 191, 2015 Apr 01.
Article in English | MEDLINE | ID: mdl-25793419
2.
Cell Death Differ ; 17(1): 14-24, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19893571

ABSTRACT

The study of death receptor (DR) signaling has led to the discovery of new signaling paradigms, including the first example of direct receptor-mediated activation of a protease (caspase-8) that functions as a second messenger to initiate a 'death cascade' of downstream protease activation. More recently, this receptor system has underscored the importance of ubiquitin modification in NF-kappaB activation. Both degradative lysine 48-linked polyubiquitin and scaffolding lysine 63-linked polyubiquitin have an essential role in signal propagation. Remarkably, a negative feedback process, termed ubiquitin editing, regulates signaling that emanates from certain DRs. Ubiquitin editing is mediated by a complex interplay between the ubiquitination and deubiquitination machinery, resulting in the replacement of signal enhancing lysine 63-linked polyubiquitin with signal extinguishing lysine 48-linked polyubiquitin. The ubiquitination machinery and its regulation in the context of DR signaling are discussed herein.


Subject(s)
Receptors, Death Domain/metabolism , Ubiquitin/metabolism , CARD Signaling Adaptor Proteins/metabolism , Caspase 8/metabolism , Fas-Associated Death Domain Protein/metabolism , Signal Transduction , TNF Receptor-Associated Death Domain Protein/metabolism , Ubiquitination
3.
J Biol Chem ; 275(15): 11470-7, 2000 Apr 14.
Article in English | MEDLINE | ID: mdl-10753965

ABSTRACT

Apoptosis inhibition rather than enhanced cellular proliferation occurs in prostate cancer (CaP), the most commonly diagnosed malignancy in American men. Therefore, it is important to characterize residual apoptotic pathways in CaP cells. When intracellular Ca(2+) stores are released and plasma membrane "store-operated" Ca(2+) entry channels subsequently open, cytosolic [Ca(2+)] increases and is thought to induce apoptosis. However, cells incapable of releasing Ca(2+) stores are resistant to apoptotic stimuli, indicating that Ca(2+) store release is also important. We investigated whether release of intracellular Ca(2+) stores is sufficient to induce apoptosis of the CaP cell line LNCaP. We developed a method to release stored Ca(2+) without elevating cytosolic [Ca(2+)]; this stimulus induced LNCaP cell apoptosis. We compared the apoptotic pathways activated by intracellular Ca(2+) store release with the dual insults of store release and cytosolic [Ca(2+)] elevation. Earlier processing of caspases-3 and -7 occurred when intracellular store release was the sole Ca(2+) perturbation. Apoptosis was attenuated in both conditions in stable transfected cells expressing antiapoptotic proteins Bclx(L) and catalytically inactive caspase-9, and in both scenarios inactive caspase-9 became complexed with caspase-7. Thus, intracellular Ca(2+) store release initiates an apoptotic pathway similar to that elicited by the dual stimuli of cytosolic [Ca(2+)] elevation and intracellular store release.


Subject(s)
Apoptosis , Calcium/metabolism , Prostatic Neoplasms/pathology , Caspase 7 , Caspase 9 , Caspases/physiology , Endoplasmic Reticulum/metabolism , Humans , Male , Nickel/pharmacology , Proto-Oncogene Proteins c-bcl-2/physiology , Thapsigargin/pharmacology , Tumor Cells, Cultured , Tumor Suppressor Protein p53/physiology , bcl-X Protein
4.
Trends Biochem Sci ; 21(10): 359-64, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8918187

ABSTRACT

The experimental study and manipulation of programmed cell death has been greatly assisted by the identification of genetic and pharmacological tools that can either induce or block cell lethality. This review discusses new insights into the molecular sensing of perturbations induced by such tools, as well as the possible consequences of this detection in determining cell survival.


Subject(s)
Apoptosis/physiology , Amyloid/pharmacology , Apoptosis/drug effects , Apoptosis/genetics , Chelating Agents/pharmacology , Cytoskeleton/chemistry , DNA Damage/genetics , Ion Channels/metabolism , Oxidants/pharmacology , Receptors, Cell Surface/metabolism , Signal Transduction/genetics , Tumor Necrosis Factor-alpha/pharmacology
5.
Hum Pathol ; 27(6): 573-80, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8666367

ABSTRACT

The prognostic value of the p53 gene (TP53), the most commonly mutated gene in human cancers, has been well established for several cancer types. However, because varying frequencies of TP53 mutations have been identified in prostatic adenocarcinoma (CaP) by genetic and immunohistochemical (IHC) studies, the role of TP53 in CaP tumorigenesis is currently unresolved. These experimental discrepancies could be caused by tissue heterogeneity within prostatic neoplasms, variations in experimental protocols, or other factors. Thus, the goal of this study was to develop a reliable IHC approach for the detection of p53 in archival prostate tissue. The authors evaluated four p53 antibodies, CM-1, 1801, DO-1, and DO-7, for their ability to reveal p53. They chose two reference CaP cell lines, 26 patient specimens (including eight benign prostatic hyperplasias (BPHs), 16 CaPs, and two lymph node metastases), one prostate and nine kidney cell lines for p53 analysis. The TP53 status of these samples was characterized using single-strand conformational polymorphism (SSCP) analysis of RNA/PCR products and sequencing. IHC detection of p53 was markedly enhanced by using the combination of microwave heat-induced antigen unmasking and a cocktail of the DO-1 and DO-7 antibodies. This approach identified 14 of 15 (93%) cell lines and patient samples having TP53 missense mutations in the exons 5 to 8 region. Of the 21 patient samples and cell lines that were either normal by SSCP or expressed p53 mutations that are not expected to stain, 18 (86%) were immunonegative. Because of this good correlation between molecular and IHC analysis, this approach may help to resolve the uncertainty about TP53 in CaP tumorigenesis.


Subject(s)
Genes, p53 , Mutation , Prostatic Diseases/genetics , Prostatic Diseases/pathology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Tumor Suppressor Protein p53/genetics , Adenocarcinoma/chemistry , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Antibodies, Monoclonal/chemistry , Antigens, Neoplasm/immunology , Humans , Immunohistochemistry , Male , Prostatic Diseases/metabolism , Prostatic Hyperplasia/genetics , Prostatic Hyperplasia/metabolism , Prostatic Hyperplasia/pathology , Prostatic Neoplasms/chemistry , Staining and Labeling , Tumor Suppressor Protein p53/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...